Deucravacitinib
Deucravacitinib is a pharmaceutical drug with 51 clinical trials. Currently 26 active trials ongoing. Historical success rate of 68.4%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
12
Mid Stage
23
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
59.1%
13 of 22 finished
40.9%
9 ended early
26
trials recruiting
51
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Deucravacitinib in the Treatment of Cicatricial Alopecias
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Clinical Trials (51)
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Deucravacitinib in the Treatment of Cicatricial Alopecias
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Correction of Psoriatic T Cell Signatures by Deucravacitinib
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Vitiligo Treatment by Targeting TYK2 Mediated Responses
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 51